Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of deucravacitinib in active psoriatic arthritis biologic-naïve patients
2020-005097-10Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Deucravacitinib with Placebo (2 arms). Primary endpoint: ACR20 response. Started May 2021; status: active.
02
Drugs
deucravacitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2020-005097-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005097-10.